ATLASLineage Cell Therapeutics (LCTX) earnings date: Nov 5, 2026
Lineage Cell Therapeutics (LCTX) reports earnings for the quarter ended Sep 30, 2026 on Thu, Nov 5, 2026, after the close. Analysts expect EPS of -$0.02.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on LCTX
| Last price | $1.01 (+1.0%) |
|---|---|
| Normal 1-day range (±1σ) | ±3.4% |
| Earnings beat history | Beat the EPS estimate in 2 of the last 4 reports |
These figures come from the same calibrated model and valuation as the Lineage Cell Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Lineage Cell Therapeutics reports on Nov 5, 2026. One email the day before, with ATLAS’s read on Lineage Cell Therapeutics. You can switch it off at any time.
Alert me before LCTX reportsFree to start. Creating an account takes under a minute.
Notify me when Lineage Cell Therapeutics reports
Track LCTX free Add Lineage Cell Therapeutics to a free ATLAS watchlist and see its next report date in one place.
LCTX earnings at a glance
| Next report (confirmed) | Thu, Nov 5, 2026 |
|---|---|
| Time | After the close |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.02 |
| Last report | Aug 6, 2026 · Beat |
| Beat rate (last 4 reports) | 2 of 4 (50%) |
| Average EPS surprise | -41.5% |
| Average move around a report | ±2.6% (last 4) |
| Sector | Healthcare · Biotechnology |
Lineage Cell Therapeutics earnings history: last 4 reports
Lineage Cell Therapeutics last reported on Aug 6, 2026: EPS of $0.01 against an estimate of -$0.03 (+133.3% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 6, 2026 | -$0.03 | $0.01 | +133.3% | Beat | -3.5% |
| May 26, 2026 | $2.34 | $3.14 | +34.2% | Beat | 0.0% |
| Jan 28, 2026 | $1.03 | $1.03 | 0.0% | In line | -3.7% |
| Nov 6, 2025 | -$0.03 | -$0.13 | -333.3% | Miss | -3.3% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for LCTX
See the fair value, the probability range and the earnings history of Lineage Cell Therapeutics on its ATLAS page.
Lineage Cell Therapeutics (LCTX) stock analysisPlans from €3.99 a month.
Lineage Cell Therapeutics earnings: frequently asked questions
When does Lineage Cell Therapeutics (LCTX) report earnings?
Lineage Cell Therapeutics is scheduled to report on Thursday, November 5, 2026, after the close. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for LCTX?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.02 per share (USD). Estimates can change before the report.
How often does LCTX beat earnings estimates?
Of its last 4 reports with a recorded result, Lineage Cell Therapeutics beat the EPS estimate 2 times; the average surprise was -41.5%. Past results do not predict the next one.
How much does LCTX move around earnings?
Over its last 4 reports the stock moved an average of 2.6% (absolute, from the close before the report day to the close after it), and finished higher 0 of 4 times.
Did Lineage Cell Therapeutics beat earnings estimates last quarter?
Lineage Cell Therapeutics last reported on Aug 6, 2026: EPS of $0.01 against an estimate of -$0.03 (+133.3% surprise), a beat.
How much does LCTX usually move in a day?
On a normal trading day the ATLAS model puts LCTX’s one-day range at about ±3.4%, with a 50% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Thu, Nov 5, 2026
Educational information, not investment advice. Disclaimer